PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-30.95%
Negative net income growth while AGEN stands at 14.23%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
-12.50%
Both reduce yoy D&A, with AGEN at -0.33%. Martin Whitman would suspect a lull in expansions or intangible additions for both.
No Data
No Data available this quarter, please select a different quarter.
-0.29%
Both cut yoy SBC, with AGEN at -2.87%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
710.07%
Slight usage while AGEN is negative at -61.56%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
478.18%
AP growth well above AGEN's 118.77%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
8.45%
Lower 'other working capital' growth vs. AGEN's 2225.75%. David Dodd would see fewer unexpected short-term demands on cash.
-100.00%
Negative yoy while AGEN is 178.91%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-8.11%
Negative yoy CFO while AGEN is 0.03%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
100.00%
Some CapEx rise while AGEN is negative at -1217.14%. John Neff would see competitor possibly building capacity while we hold back expansions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
We have mild expansions while AGEN is negative at -203.49%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
-50.00%
Both yoy lines negative, with AGEN at -3.10%. Martin Whitman suspects an environment prompting net new borrowings or weaker paydowns across the niche.
-32.24%
Both yoy lines negative, with AGEN at -88.41%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.